New findings reveal promising efficacy of irpagratinib and atezolizumab in treating advanced hepatocellular carcinoma with FGF19 overexpression.
August 2025
Trifluridine/tipiracil shows potential in improving disease-free survival in colorectal cancer patients post-surgery, despite safety concerns.
Atezolizumab and bevacizumab enhance TACE effectiveness, significantly extending progression-free survival in unresectable HCC patients, as shown in the TALENTACE trial.
Menin inhibitors emerge as a breakthrough in treating acute myeloid leukemia, showcasing promising results at the 2025 EHA Congress.
Medical practices face staffing shortages and rising costs, prompting innovative strategies for health benefits to enhance recruitment and retention.
Precision medicine revolutionizes cancer care, empowering patients with personalized insights and targeted therapies while addressing implementation challenges in community oncology.
Robert L. Ferris, MD, PhD, pens this month's editor-in-chief column for Targeted Therapies in Oncology.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
3
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
4
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
5
